Skye Bioscience Inc (FRA:09R)

Q2 2025 Skye Bioscience Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: €3.16 (+2.60%)

Transcript 8-K10-Q

Key Points

Positve

Skye Bioscience Inc (SKYE) completed enrollment for its Phase 2A CBon trial ahead of schedule, with the 26-week visit for the last patient projected to occur soon.
The Data Safety Monitoring Committee has reviewed the study four times without recommending any changes, indicating a well-managed program.
Nemasimab, the company's CB1 antibody, shows negligible brain penetration, potentially reducing central toxicity and offering a broader therapeutic window.
Pre-clinical studies suggest Nemasimab can enhance the efficacy of sub-optimal doses of other treatments, offering potential for combination strategies.
Skye Bioscience Inc (SKYE) ended the second quarter with $48.6 million in cash and equivalents, projected to fund operations through at least Q1 2027.

Negative

Research and development expenses increased significantly to $14.3 million in Q2 2025 from $4.1 million in the same period in 2024.
The net loss for Q2 2025 was $17.6 million, more than double the $7.9 million loss in Q2 2024.
Approximately 50% of patients from the original study are eligible for the extension study, potentially limiting the data set for long-term analysis.
The company faces a competitive landscape with high discontinuation rates for existing obesity treatments, which could impact market penetration.
The follow-up data for the extension study, including durability of weight loss, will not be available until the first half of 2026, delaying comprehensive results.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SKYE.OQ - Skye Bioscience Inc
Q2 2025 Skye Bioscience Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by. My name is Yi, and I will be a conference operative today.

At this time I would like to welcome everyone to the Sky Bioscience 2nd quarter 2025 financial results and business update call.

All lines have been placed on me to prevent any background noise.

After the speaker's remarks, there will be a question and answer session.

Oh now let's turn the conference over to Bernie Hertel, head of investor relations. Please go.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Ahead. Hello, and.

--

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.